Leadership Team Jasper Therapeutics’ management team is composed of experienced biopharma industry veterans with extensive track records in drug development and commercialization. With this leadership, we are well positioned to achieve our vision of developing new therapies to treat both chronic and life...
REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to ...
第一资本维持Jasper Therapeutics(JSPR.US)买入评级,维持目标价55美元 第一资本分析师Tim Chiang维持$Jasper Therapeutics(JSPR.US)$买入评级,维持目标价55美元。根据TipRanks数据显示,该分析师近一年总胜率为37.4%,总平均回报率为-11.6%。提示: TipRanks为独立第三方,提供金融分析师的分析数据,并计算分析师推荐的平...
Jasper Therapeutics, Inc.于2019年8月13日在特拉华州成立,是一家生物技术公司,专注于开发基于造血干细胞生物学的新型治疗方法。该公司正在推进两项可能具有开创性的计划。JSP191是一种抗CD117单克隆抗体,作为一种调理剂正在临床开发中,用于清除接受造血细胞移植的患者骨髓中的造血干细胞。它旨在实现更安全、更有效的...
jaspertherapeutics.com Overview & Products Financials Founded Year 2018 Stage Reverse Merger| IPO Total Raised $49.1M Market Cap 0.30B Stock Price 19.55 About Jasper Therapeutics Jasper Therapeutics is a biotechnology company that focuses on targeting mast cells and stem cells to treat chronic diseases...
加拿大皇家银行:维持Jasper Therapeutics(JSPR.US)评级,由优于大市调整至优于大市评级, 目标价由70.00美元调整至68.00美元。 Jasper Therapeutics(JSPR.US)公司简介:Jasper Therapeutics Inc 是一家临床阶段的生物技术公司,致力于通过造血干细胞疗法实现治愈。 它专注于更安全、更有效的调理剂和干细胞工程的开发和商业...
Retrieve the quarterly and annual income statements for Jasper Therapeutics (JSPR). Find out the revenue, expenses and profit or loss over the last fiscal year. Export or download to CSV or Excel file.
jasper therapeutics presents data from preclinical briquilimab studies at the american academy of allergy, asthma, and immunology (aaaai) annual meeting jasper therapeutics在美国过敏,哮喘和免疫学学会(aaaai)年会上公布了来自briquilimab临床前研究的数据 jasper therapeutics · 02/23 13:00 jspr +0.11% ...
“c-Kit inhibitors are a promising class of monoclonal therapeutics with demonstrated efficacy in mast cell driven diseases,” said Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité – Universitätsmedizin in Berlin. “As a potent and differentiated c-Ki...
10/15,Jasper Therapeutics$Jasper Therapeutics(JSPR)$的股价在周一上涨了多达11%,原因是公司报告了其靶向CD117的单克隆抗体briquilimab在治疗肥大细胞驱动疾病(包括慢性自发性荨麻疹(CSU)、慢性诱发性荨麻疹和哮喘)中的早中期研究的积极结果。 这项Ib/IIa期SPOTLIGHT试验正在评估briquilimab的单次皮下注射剂量,针对...